Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt 1.43
XOMA's Cash to Debt is ranked lower than
75% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. XOMA: 1.43 )
Ranked among companies with meaningful Cash to Debt only.
XOMA' s 10-Year Cash to Debt Range
Min: 0.01  Med: 1.04 Max: No Debt
Current: 1.43
Equity to Asset -0.17
XOMA's Equity to Asset is ranked lower than
94% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. XOMA: -0.17 )
Ranked among companies with meaningful Equity to Asset only.
XOMA' s 10-Year Equity to Asset Range
Min: -0.77  Med: 0.01 Max: 0.82
Current: -0.17
-0.77
0.82
F-Score: 1
Z-Score: -18.68
M-Score: -3.57
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -446.93
XOMA's Operating margin (%) is ranked lower than
72% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -71.01 vs. XOMA: -446.93 )
Ranked among companies with meaningful Operating margin (%) only.
XOMA' s 10-Year Operating margin (%) Range
Min: -2191.67  Med: -180.30 Max: 13.17
Current: -446.93
-2191.67
13.17
Net-margin (%) -305.57
XOMA's Net-margin (%) is ranked lower than
67% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. XOMA: -305.57 )
Ranked among companies with meaningful Net-margin (%) only.
XOMA' s 10-Year Net-margin (%) Range
Min: -2153.94  Med: -203.70 Max: 14.89
Current: -305.57
-2153.94
14.89
ROA (%) -63.43
XOMA's ROA (%) is ranked lower than
76% of the 848 Companies
in the Global Biotechnology industry.

( Industry Median: -26.61 vs. XOMA: -63.43 )
Ranked among companies with meaningful ROA (%) only.
XOMA' s 10-Year ROA (%) Range
Min: -139.63  Med: -59.54 Max: 4.68
Current: -63.43
-139.63
4.68
ROC (Joel Greenblatt) (%) -951.79
XOMA's ROC (Joel Greenblatt) (%) is ranked lower than
60% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. XOMA: -951.79 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
XOMA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1636.29  Med: -236.98 Max: 46.51
Current: -951.79
-1636.29
46.51
Revenue Growth (3Y)(%) -55.70
XOMA's Revenue Growth (3Y)(%) is ranked lower than
85% of the 402 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. XOMA: -55.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
XOMA' s 10-Year Revenue Growth (3Y)(%) Range
Min: -60.9  Med: -21.30 Max: 147.7
Current: -55.7
-60.9
147.7
EBITDA Growth (3Y)(%) -29.20
XOMA's EBITDA Growth (3Y)(%) is ranked lower than
80% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. XOMA: -29.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
XOMA' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -39.7  Med: -20.10 Max: 31.1
Current: -29.2
-39.7
31.1
EPS Growth (3Y)(%) -29.80
XOMA's EPS Growth (3Y)(%) is ranked lower than
78% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. XOMA: -29.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
XOMA' s 10-Year EPS Growth (3Y)(%) Range
Min: -53  Med: -11.60 Max: 36.5
Current: -29.8
-53
36.5
» XOMA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

XOMA Guru Trades in Q4 2013

Paul Tudor Jones 20,425 sh (New)
» More
Q1 2014

XOMA Guru Trades in Q1 2014

John Burbank 49,774 sh (New)
Louis Moore Bacon 75,000 sh (New)
Paul Tudor Jones 33,233 sh (+62.71%)
» More
Q2 2014

XOMA Guru Trades in Q2 2014

Louis Moore Bacon 75,000 sh (unchged)
John Burbank Sold Out
Paul Tudor Jones Sold Out
» More
Q3 2014

XOMA Guru Trades in Q3 2014

Louis Moore Bacon Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with XOMA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 24.62
XOMA's P/S is ranked lower than
68% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.51 vs. XOMA: 24.62 )
Ranked among companies with meaningful P/S only.
XOMA' s 10-Year P/S Range
Min: 0.55  Med: 5.90 Max: 63.23
Current: 24.62
0.55
63.23
Current Ratio 2.75
XOMA's Current Ratio is ranked lower than
66% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.38 vs. XOMA: 2.75 )
Ranked among companies with meaningful Current Ratio only.
XOMA' s 10-Year Current Ratio Range
Min: 0.63  Med: 3.04 Max: 6.65
Current: 2.75
0.63
6.65
Quick Ratio 2.75
XOMA's Quick Ratio is ranked lower than
62% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. XOMA: 2.75 )
Ranked among companies with meaningful Quick Ratio only.
XOMA' s 10-Year Quick Ratio Range
Min: 0.63  Med: 3.04 Max: 6.65
Current: 2.75
0.63
6.65
Days Sales Outstanding 65.93
XOMA's Days Sales Outstanding is ranked lower than
54% of the 557 Companies
in the Global Biotechnology industry.

( Industry Median: 61.10 vs. XOMA: 65.93 )
Ranked among companies with meaningful Days Sales Outstanding only.
XOMA' s 10-Year Days Sales Outstanding Range
Min: 7.93  Med: 77.46 Max: 882.08
Current: 65.93
7.93
882.08

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 4.34
XOMA's Price/Median PS Value is ranked lower than
90% of the 539 Companies
in the Global Biotechnology industry.

( Industry Median: 1.17 vs. XOMA: 4.34 )
Ranked among companies with meaningful Price/Median PS Value only.
XOMA' s 10-Year Price/Median PS Value Range
Min: 0.1  Med: 2.06 Max: 69.99
Current: 4.34
0.1
69.99
Earnings Yield (Greenblatt) (%) -11.76
XOMA's Earnings Yield (Greenblatt) (%) is ranked lower than
68% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. XOMA: -11.76 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
XOMA' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -11.76  Med: 16.30 Max: 21.8
Current: -11.76
-11.76
21.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:X0M.Germany,
XOMA Corp was incorporated in Delaware in 1981 and became a Bermuda-exempted company in December 1998. The Company discovers and develops antibody-based therapeutics. Several of its antibodies have properties due to their interaction at allosteric sites on specific protein rather than the orthosteric, or active sites. The compounds are designed to either enhance or diminish the protein's activity as desired. Its lead product candidate, gevokizumab, is a proprietary potent, humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). It is also developing XOMA 3AB, a combination, or cocktail, of antibodies designed to neutralize the most potent of botulinum toxins. Its geographic segments include United States, Europe, and Asia Pacific. The Company's competitors include AbbVie Inc., Biovitrum AB, Allergan, Novartis AG, pSivida, Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., and Emergent BioSolutions, Inc. In addition to regulations in the United States, the Company is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of any future products.
» More Articles for XOMA

Headlines

Articles On GuruFocus.com
Biotech Effectiveness: Horizon Pharma, Zafgen, XOMA Corp Mar 09 2015 
comment on XOMA Mar 06 2013 
XOMA Ltd. Reports Operating Results (10-K) Mar 10 2011 
XOMA Ltd. Reports Operating Results (10-K/A) Dec 27 2010 
XOMA Ltd. Reports Operating Results (10-Q/A) Nov 12 2010 
XOMA Ltd. Reports Operating Results (10-Q) May 06 2010 
XOMA Ltd. Reports Operating Results (10-Q) Aug 06 2009 
XOMA Ltd. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
Lightning Round: Earnings on this are suspect Jun 25 2015
XOMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Jun 24 2015
XOMA Corp. (XOMA) Looks Good: Stock Moves Up 10.3% - Tale of the Tape Jun 23 2015
Mid-Afternoon Market Update: Dow Surges Over 100 Points; Avalanche Biotechnologies Shares Dip... Jun 16 2015
Mid-Day Market Update: Coty Jumps On Report of Deal With P&G; Tahoe Resources Shares Drop Jun 16 2015
Mid-Morning Market Update: Markets Rise; FactSet Profit Beats Estimates Jun 16 2015
XOMA Receives Orphan Drug Designation for XOMA 358 From U.S. FDA for Treatment of Congenital... Jun 16 2015
XOMA Receives Orphan Drug Designation for XOMA 358 From U.S. FDA for Treatment of Congenital... Jun 16 2015
These Biotech Stocks Could Deliver Big Returns for Investors Jun 15 2015
Kingdon Capital Raises Stakes in XOMA Corp (XOMA) and Heron Therapeutics Inc (HRTX) Jun 08 2015
XOMA Corp Looks Good: Stock Gains 7.8% in Session - Tale of the Tape May 29 2015
XOMA Stock Gains After Reaching Necessary Number of Events to Analyze Behcets Disease Drug Study May 28 2015
XOMA Announces Phase 3 EYEGUARD(TM)-B Study Reaches Target Exacerbation Event May 28 2015
XOMA Announces Phase 3 EYEGUARD(TM)-B Study Reaches Target Exacerbation Event May 28 2015
XOMA CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 26 2015
XOMA CORP Financials May 15 2015
10-Q for XOMA Corp. May 09 2015
Xoma reports 1Q loss May 07 2015
Xoma reports 1Q loss May 07 2015
XOMA Corp Earnings Call scheduled for 4:30 pm ET today May 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK